Dublin, Jan. 10, 2025 (GLOBE NEWSWIRE) — The “Cell Surface Marker Detection Market by Product, by Application, by End-User, and By Region” report has been added to ResearchAndMarkets.com’s offering.
The rapid expansion of the cell surface marker detection market is anticipated to continue, with expectations for it to rise from USD 5.76 billion in 2023 to over USD 14 billion by 2034, achieving a compound annual growth rate (CAGR) of 8.43% during a forecast period from 2024 to 2034. This projected market growth is fueled by an increase in the demand for advanced diagnostics, particularly in the face of growing prevalence of cancer and the drive for personalized medicine.
Medical Advancements Spur Market Growth
Advancements in diagnostic technologies and the demand for early disease detection are poised to contribute to the surge in the cell surface marker detection market. This is particularly important in the context of rising cancer incidences, as reported by the American Cancer Society. In response to this urgent need, the industry has witnessed significant strides such as the development of reagents & kits that have become essential tools in delivering accurate diagnostic results.
Innovation in Diagnostic Tools
The advent of new technologies, such as AI-driven hematology analyzers, continues to revolutionize the market. These innovative tools play a pivotal role in enhancing clinic workflow and patient outcomes while allowing veterinary and healthcare providers to operate more efficiently.
Research and Drug Discovery Fuel Demand
The persistent demand for precise disease diagnosis and the growing focus on drug discovery and personalized medicine are driving the cell surface marker detection market to new heights. The segment dedicated to pharmaceuticals and biotechnology companies has emerged as the top revenue contributor based on their significant investments and reliance on these advanced diagnostic technologies.
Regional Market Insights
The North American market claims the highest revenue share due to leading healthcare partners in the region, followed closely by the Asia Pacific market, which is anticipated to experience the fastest growth during the forecast period. Improvement in healthcare infrastructure and increasing research and development endeavors play significant roles in the APAC region’s market evolution.
With the healthcare landscape rapidly evolving, stakeholders across the industry are keeping a close watch on the various market trends and innovations shaping the future of cell surface marker detection and its applications in disease diagnosis and personalized therapies.
The continuous research and reports provide a thorough analysis of the market scope, including a detailed segmentation of the industry by product, application, end-user, and geographic region, to deliver an in-depth understanding of the cell surface marker detection market’s current state and its potential growth trajectory over the coming decades.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 200 |
| Forecast Period | 2023 – 2034 |
| Estimated Market Value (USD) in 2023 | $5.76 Billion |
| Forecasted Market Value (USD) by 2034 | $14.02 Billion |
| Compound Annual Growth Rate | 8.4% |
| Regions Covered | Global |
Companies Featured
- BD Biosciences
- Beckman Coulter (a subsidiary of Danaher Corporation)
- Thermo Fisher Scientific
- Merck KGaA (MilliporeSigma in the U.S.)
- Bio-Rad Laboratories
- Abbott Laboratories
- Glycotope GmbH
- R&D Systems (a part of Bio-Techne Corporation)
- Luminex Corporation
- Miltenyi Biotec
- Agenus Inc.
- Stemcell Technologies
- Illumina Inc.
- Qiagen N.V.
- CureVac AG.
For more information about this report visit https://www.researchandmarkets.com/r/3vcyt2
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Global Cell Surface Marker Detection Market
